Loading clinical trials...
Loading clinical trials...
The Hispanic/Latinx community (hereafter Hispanic) is the country's second-largest racial/ethnic group, accounting for 19.1% of the total population. However, they remain one of the most underserved populations with suboptimal access to healthcare and screening services due to low income, lack of health insurance, perceived discrimination, language barriers, and limited health literacy. Lung cancer is the leading cause of cancer related mortality with 1.8 million annual deaths worldwide, with Hispanic patients known to have lower survival rates compared with non-Hispanic whites. Lung cancer screening (LCS) with low dose computed tomography (LDCT) decreases this mortality rate of lung cancer by 20%. Yet many Latinx patients who are eligible for lung cancer screening are still falling through the cracks which prevents patients the ability to detect lung cancer early. This study will test and compare the effect of a multi-level intervention on ordering LDCT within 4 months after patient enrollment to those in an Enhanced Usual Care. Our proposed intervention includes: * Primary care provider notifications of patients' LCS eligibility; * Patients' education; * Patients' referral to financial navigation resources; * Patients' reminder to discuss LCS during primary care provider (PCP) visit.
Age
50 - 80 years
Sex
ALL
Healthy Volunteers
Yes
UCI Health Family Health Center - Anaheim
Anaheim, California, United States
UCI Health-Costa Mesa
Costa Mesa, California, United States
UCI Health-Irvine
Irvine, California, United States
UCI Health-Laguna hilla
Laguna Hills, California, United States
UCI Health-Newport
Newport Beach, California, United States
UCI Health SeniorHealth Center -Pavillion 4
Orange, California, United States
UCI Medical Center, Pavilion 3
Orange, California, United States
UCI Health Family Health Center - Santa Ana
Santa Ana, California, United States
UCI-Health Tustin
Tustin, California, United States
UCI Health-Yorba Linda
Yorba Linda, California, United States
Start Date
February 12, 2024
Primary Completion Date
December 11, 2025
Completion Date
February 1, 2026
Last Updated
January 22, 2026
60
ESTIMATED participants
Usual Care
OTHER
Brief Patient Education
BEHAVIORAL
Patient education
BEHAVIORAL
Referral to financial navigation resources
BEHAVIORAL
Patient Reminders
BEHAVIORAL
Provider Reminders
BEHAVIORAL
Lead Sponsor
University of California, Irvine
Collaborators
NCT06305754
NCT06498635
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions